Synaptogenix moves forward with clinical development plans for bryostatin-1 as a treatment for multiple sclerosis

New york, feb. 23, 2022 /prnewswire/ -- synaptogenix, inc. (nasdaq: snpx), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced plans to develop bryostatin-1 for the treatment of multiple sclerosis ("ms"), a third indication for the drug candidate. the company will collaborate with the cleveland clinic through a new consulting agreement.
SNPX Ratings Summary
SNPX Quant Ranking